Photoactivation of MDM2 Inhibitors: Controlling Protein–Protein Interaction with Light
摘要:
Selectivity remains a major challenge in anticancer therapy, which potentially can be overcome by local activation of a cytotoxic drug. Such triggered activation can be obtained through modification of a drug with a photoremovable protecting group (PPG), and subsequent irradiation in the chosen place and time. Herein, the design, synthesis and biological evaluation is described of a photoactivatable MDM2 inhibitor, PPG-idasanutlin, which exerts no functional effect on cellular outgrowth, but allows for the selective, noninvasive activation of antitumor properties upon irradiation visible light, demonstrating activation with micrometer, single cell precision. The generality of this method has been demonstrated by growth inhibition of multiple cancer cell lines showing p53 stabilization and subsequent growth inhibition effects upon irradiation. Light activation to regulate protein-protein interactions between MDM2 and p53 offers exciting opportunities to control a multitude of biological processes and has the potential to circumvent common selectivity issues in antitumor drug development.
NOVEL N-SUBSTITUTED-PYRROLIDINES AS INHIBITORS OF MDM2-P-53 INTERACTIONS
申请人:Bartkovitz David Joseph
公开号:US20110086854A1
公开(公告)日:2011-04-14
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, and R
5
are as described herein
and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.
There are provided compounds of the formula
wherein X, Y, R
1
, R
2
, R
3
, R
3
, R
4
, R
5
, R
6
and R
7
are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.
There are provided compounds of formula I
or a pharmaceutically acceptable salt thereof,
wherein X, Y, R
1
, R
1′
, R
2
, R
2′
, R
3
, R
4
, R
5
are as defined herein. The compounds exhibit activity as anticancer agents.
[EN] MDM2 DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION DE MDM2 ET LEURS UTILISATIONS
申请人:KYMERA THERAPEUTICS INC
公开号:WO2021188948A1
公开(公告)日:2021-09-23
The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.
[EN] PHOTORESPONSIVE NUTLIN DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE NUTLINE PHOTOSENSIBLES ET LEURS UTILISATIONS
申请人:UNIV GRONINGEN
公开号:WO2020071911A1
公开(公告)日:2020-04-09
The invention relates to the field of medicine and medicinal chemistry, more in particular to the design, manufacture and use of anti-cancer drugs that can be activated by an external stimulus that can be applied in a spatiotemporal fashion. Provided herein is a compound having the chemical structure or a pharmaceutically acceptable salt thereof.